# Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

> **NCT01946477** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 186 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT01946477
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-29
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-05-26
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01946477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01946477, "Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01946477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*